Literature DB >> 31461377

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

Panagiotis A Konstantinopoulos1, Weixiu Luo1, Joyce F Liu1, Doga C Gulhan2, Carolyn Krasner1, Jeffrey J Ishizuka1, Allison A Gockley3, Mary Buss4, Whitfield B Growdon5, Heather Crowe5, Susana Campos1, Neal I Lindeman3, Sarah Hill3, Elizabeth Stover1, Susan Schumer1, Alexi A Wright1, Jennifer Curtis1, Roxanne Quinn1, Christin Whalen1, Kathryn P Gray1, Richard T Penson5, Stephen A Cannistra4, Gini F Fleming6, Ursula A Matulonis1.   

Abstract

PURPOSE: Despite the tissue-agnostic approval of pembrolizumab in mismatch repair deficient (MMRD) solid tumors, important unanswered questions remain about the role of immune checkpoint blockade in mismatch repair-proficient (MMRP) and -deficient endometrial cancer (EC).
METHODS: This phase II study evaluated the PD-L1 inhibitor avelumab in two cohorts of patients with EC: (1) MMRD/POLE (polymerase ε) cohort, as defined by immunohistochemical (IHC) loss of expression of one or more mismatch repair (MMR) proteins and/or documented mutation in the exonuclease domain of POLE; and (2) MMRP cohort with normal IHC expression of all MMR proteins. Coprimary end points were objective response (OR) and progression-free survival at 6 months (PFS6). Avelumab 10 mg/kg intravenously was administered every 2 weeks until progression or unacceptable toxicity.
RESULTS: Thirty-three patients were enrolled. No patient with POLE-mutated tumor was enrolled in the MMRD cohort, and all MMRP tumors were not POLE-mutated. The MMRP cohort was closed at the first stage because of futility: Only one of 16 patients exhibited both OR and PFS6 responses. The MMRD cohort met the predefined primary end point of four ORs after accrual of only 17 patients; of 15 patients who initiated avelumab, four exhibited OR (one complete response, three partial responses; OR rate, 26.7%; 95% CI, 7.8% to 55.1%) and six (including all four ORs) PFS6 responses (PFS6, 40.0%; 95% CI, 16.3% to 66.7%), four of which are ongoing as of data cutoff date. Responses were observed in the absence of PD-L1 expression. IHC captured all cases of MMRD subsequently determined by polymerase chain reaction or genomically via targeted sequencing.
CONCLUSION: Avelumab exhibited promising activity in MMRD EC regardless of PD-L1 status. IHC for MMR assessment is a useful tool for patient selection. The activity of avelumab in MMRP/non-POLE-mutated ECs was low.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31461377     DOI: 10.1200/JCO.19.01021

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


  40 in total

1.  Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.

Authors:  Fausto Petrelli; Michele Ghidini; Antonio Ghidini; Gianluca Tomasello
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

Review 2.  Targeting the DNA damage response in immuno-oncology: developments and opportunities.

Authors:  Roman M Chabanon; Mathieu Rouanne; Christopher J Lord; Jean-Charles Soria; Philippe Pasero; Sophie Postel-Vinay
Journal:  Nat Rev Cancer       Date:  2021-08-10       Impact factor: 60.716

Review 3.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

4.  Optimizing immunotherapy for gynecologic cancers.

Authors:  Maria M Rubinstein; Vicky Makker
Journal:  Curr Opin Obstet Gynecol       Date:  2020-02       Impact factor: 1.927

5.  Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.

Authors:  Marina Stasenko; Irina Tunnage; Charles W Ashley; Maria M Rubinstein; Alicia J Latham; Arnaud Da Cruz Paula; Jennifer J Mueller; Mario M Leitao; Claire F Friedman; Vicky Makker; Robert A Soslow; Deborah F DeLair; David M Hyman; Dimitriy Zamarin; Kaled M Alektiar; Carol A Aghajanian; Nadeem R Abu-Rustum; Britta Weigelt; Karen A Cadoo
Journal:  Gynecol Oncol       Date:  2019-11-19       Impact factor: 5.482

6.  Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

Authors:  Panagiotis A Konstantinopoulos; Barbara Norquist; Christina Lacchetti; Deborah Armstrong; Rachel N Grisham; Paul J Goodfellow; Elise C Kohn; Douglas A Levine; Joyce F Liu; Karen H Lu; Dorinda Sparacio; Christina M Annunziata
Journal:  J Clin Oncol       Date:  2020-01-27       Impact factor: 44.544

Review 7.  Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.

Authors:  Casey M Cosgrove; David Barrington; Floor J Backes
Journal:  Curr Oncol Rep       Date:  2021-05-03       Impact factor: 5.075

Review 8.  The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities.

Authors:  Laura M Chambers; Parker Bussies; Roberto Vargas; Emily Esakov; Surabhi Tewari; Ofer Reizes; Chad Michener
Journal:  Curr Oncol Rep       Date:  2021-06-14       Impact factor: 5.075

9.  Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Authors:  Inken Salewski; Julia Henne; Leonie Engster; Bjoern Schneider; Heiko Lemcke; Anna Skorska; Peggy Berlin; Larissa Henze; Christian Junghanss; Claudia Maletzki
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

10.  Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Authors:  Yoland Antill; Peey-Sei Kok; Kristy Robledo; Sonia Yip; Michelle Cummins; Deborah Smith; Amanda Spurdle; Elizabeth Barnes; Yeh Chen Lee; Michael Friedlander; Sally Baron-Hay; Catherine Shannon; Jermaine Coward; Philip Beale; Geraldine Goss; Tarek Meniawy; Janine Lombard; John Andrews; Martin R Stockler; Linda Mileshkin
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.